Arvinas

Arvinas is a clinical-stage biotechnology company that pioneers targeted protein degradation therapeutics using its proprietary PROTAC platform. The company designs bifunctional small molecules that recruit the human cellular ubiquitin-proteasome system to degrade and eliminate disease-causing proteins, advancing vepdegestrant for ER-positive metastatic breast cancer. Through targeted protein degradation, Arvinas tackles previously undruggable targets across oncology and neurodegenerative disorders.